The largest database of trusted experimental protocols

94 protocols using cremophor

1

Cremophor Solvent for IRE1 Inhibitor Delivery

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cremophor (MilliporeSigma, 238470) was heated at 37°C to achieve liquidity and then mixed with sterile saline to obtain a 20% Cremophor solution. IRE1 Inhibitor III, 4μ8C (MilliporeSigma, CAS 14003-96-4), was resuspended in the 20% Cremophor solution and injected i.p. into the mice at a concentration of 10 mg/kg/d. Mice were injected daily, beginning 2 days before LCWE injection until day 7 after LCWE and tissue harvest. The drug was prepared fresh every day.
+ Open protocol
+ Expand
2

Anandamide Hydrolysis Inhibitor URB597 Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
URB597 (FAAH inhibitor; (3-(3-carbamoylphenyl)phenyl) N-cyclohexylcarbamate) was obtained from Cayman Chemicals (Ann Arbor, MI, USA). Rhodamine 6G, cremophor, dimethyl sulphoxide (DMSO), urethane and sodium monoiodoacetate were obtained from Sigma Aldrich (St. Louis, MO, USA).
URB597 (0.03, 0.3 and 3.0 mg/kg) was dissolved in vehicle (DMSO:cremophor:saline 1:1:8) on the day of use. MIA was dissolved in saline (0.3 mg/10 μl) on the day of use. Rhodamine 6G (0.05%) was dissolved in saline and stored in the dark at 4 °C. Physiological buffered saline (135 mM NaCl, 20 mM NaHCO3, 5 mM KCl, 1 mM MgSO4⋅7H2O, pH 7.4) was prepared in-house.
+ Open protocol
+ Expand
3

Xenograft model of Lats1/2-deficient tumor

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female athymic NCR nude mice of 6–8 weeks were used for allograft transplantations. Primary Lats1/2-deficient cells from paraspinal tumors were prepared as described above and cells within 2 passages were used in the study. 1–2 × 105 tumor cells diluted in Matrigel (Corning) and DMEM/10% FBS: 1:2 ratio were injected subcutaneously into the flanks. Serial dilution transplantation assays were performed similarly at defined cell numbers as indicated in Figure 3E. For in vivo drug treatment, beginning at the time of tumor detection, verteporfin or sorafenib was diluted in a mixture of 1:1 Cremophor (Sigma, C5135) and EtOH (95:5 v/v). Vehicle was 1:1 Cremophor (Sigma, C5135) and EtOH (95:5 v/v). Imatinib mesylate was diluted in distilled water. For single-agent studies, 50 mg kg−1 verteporfin (Li et al., 2016 (link)), 40 mg kg−1 sorafenib (Yuen et al., 2011 (link)) or 50 mg kg−1 imatinib mesylate (Iyoda et al., 2009 (link)) were administered to mice daily. For reduced drug dose treatment, we injected into nude mice sorafenib at 12.5 mg kg−1 and/or verteporfin at 10 mg kg−1, every other day for at least 30 days. Tumor size was calculated by measuring length and width of the lesion with the formula (length) × (width)2 × 0.5.
+ Open protocol
+ Expand
4

Cannabinoid Receptor Antagonist Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Norbinaltorphimine (norBNI, synthesized at the Chemical Biology Research Branch of the National Institute on Drug Abuse) was dissolved in sterile H2O at a concentration of 15 mg/ml and administered subcutaneously (SC) at a dose of 15 mg/kg. Sterile H2O was administered as vehicle to control animals at a volume equal to the 15 mg/kg dose of norBNI. Δ9-tetrahydrocannabinol (THC, generously supplied by the National Institute on Drug Abuse, NIDA) was dissolved in a solution of 5% ethanol, 5% Cremophor (Sigma-Aldrich) and 90% saline at a concentration of 1 mg/ml and administered intraperitoneally (IP) at a dose of 0.56, 1.0, 1.8 or 3.2 mg/kg. The vehicle was also prepared as a 5% ethanol, 5% Cremophor (Sigma-Aldrich) and 90% saline solution and was administered to control animals at a volume equal to the highest dose of THC administered (3.2 mg/kg). All drug, vehicle and saline solutions were filtered through a 0.2 μl syringe filter to remove any possible contaminants before being administered. Sodium saccharin (0.1%; Sigma-Aldrich) was prepared daily as a 1 g/L solution in tap water.
+ Open protocol
+ Expand
5

Targeting Melanoma Metastasis with Sorafenib

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were injected with 0.3 × 105 WT31 melanoma cells intrasplenically. From day 1 to 18 mice received daily i.p. injections of Sorafenib (Sigma-Aldrich, MS, USA) (60 mg/kg KG, diluted in 12.5% Cremophor (Sigma-Aldrich, MS, USA), 12.5% ethanol, and 75% sterile saline) or vehicle/solvent control (12.5% Cremophor, 12.5% ethanol, and 75% sterile saline). At day 19 mice were sacrificed and metastases were quantified.
+ Open protocol
+ Expand
6

LPS-Induced Inflammation and Therapeutic Interventions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lipopolysaccharide (LPS) was purchased from Sigma (Cat # L8643) and dissolved in sterile phosphate-buffered saline (PBS) prior to being administered to mice (single dose; 0.8 mg/kg, i.p.). E3330, also called APX3330 was synthesized as described (Jiang et al., 2010 (link); Nyland et al., 2010 (link)). E3330 was dissolved in Cremophor: EtOH (1:1) (Cremophor was purchased from Sigma, Cat # C5135) for stock solution generation and diluted in PBS prior to use for pre-LPS treatment or post-LPS treatment (20 mg/kg, twice a day, i.p. for Figure S6A; 20 mg/kg, one dose per day, daily by gavage for experiments in Figure 6C, 6D, 6E and Figure S6C and S6D). SHP099 (provided by Novartis), was dissolved in 0.5% Methylcellulose (Sigma, Cat# M0262) and 0.1% Tween-80 (Fisher Scientific, Cat #BP338–500) and given to animals by gavage (daily, 50 mg/kg) for all the in vivo treatments. Male and female mice between 3–4 weeks as juvenile mice, or 8–16 weeks of age as adult mice, or 6~8 month of age as aged mice, were used for indicated experiments.
+ Open protocol
+ Expand
7

Rapamycin and Oseltamivir Anti-Viral Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
Rapamycin (Cat #R5000, LC Laboratories, MA, USA) powder was dissolved in DMSO (Sigma) and aliquots were preserved in −80 °C until use. Aliquots were first diluted 1:1 with Cremophor (Cat# C-5135, Sigma) and subsequent dilutions were prepared in phosphate buffer solution (PBS) for experimental use. An appropriate concentration of the solution was directly added to the culture for assessing anti-viral activity in vitro or injected into the peritoneal cavity of mice to study effects in vivo. Oseltamivir (Tamiflu, 75 mg Oseltamivir/capsule, Roche, Switzerland) was suspended in PBS to achieve desired concentration. The solution was directly added to the culture for assessing anti-viral activity in vitro or fed orally to mice for studying effects in vivo.
+ Open protocol
+ Expand
8

Inducible Pdgfb-CreERT2 Mouse Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tamoxifen (Sigma) was dissolved in ethanol at 60mg/ml. The equivalent of 3mg was mixed at a 1:1:2 ratio with Cremophor (Sigma) and PBS and injected subcutaneously (SC) twice, with a 2 day interval. Mice were analyzed one week after the last injection, at an age of 4-5 weeks. We did not observe any toxicity of the inducible Cre, as no difference in thymic cellularity, DN1/DN2 cell number, bone marrow cellularity or lymphoid progenitor numbers were observed in Tamoxifen-induced Pdgfb-CreERT2 mice compared to non-transgenic controls (Supplementary Figure 3g-j). Likewise, no dramatic effect was observed of the Tamoxifen treatment alone on thymocyte subsets with this setting (Supplementary Figure 3k).
+ Open protocol
+ Expand
9

Melatonin Modulation of Tumor Angiogenesis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Animals were randomly assigned to either the Melatonin administration (n = 5) or the control group (vehicle treated, n = 8). Vehicle solution was prepared with 8 ml of phosphate buffered saline (PBS), 1 ml of dimethyl sulfoxide (DMSO) and 1 ml of Cremophor (Sigma, St. Louise, MO, USA). The animals of the control group received 100 µl of vehicle solution by intraperitoneal injection (IP).
Melatonin (Sigma, St. Louise, MO, USA) was diluted in vehicle and the animals from the Melatonin group received IP of 100 µl of Melatonin treatment (at dose of 40 mg/kg of body weight) for five days a week. Melatonin was administered 1 hr before room lighting was switched off. Administration of Melatonin prior to the nocturnal increase in endogenous Melatonin may be most effective because tissues are most sensitive to the hormone at this time [38] (link), [39] (link).
Melatonin or vehicle administration started on the day of tumor implantation (soon after implantation) and continued for five days a week for 21 days. On the 22nd day, all animals underwent SPECT scanning with Tc-99m-HYNIC-VEGF-c followed by euthanasia and collection of tumors for immunohistochemistry and membrane antibody array to determine the expression of different pro-angiogenic and growth factors in tumor extracts.
+ Open protocol
+ Expand
10

CBD Effects on Neuronal Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cannabidiol (2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) was obtained from Tocris Bioscience (Bio-Techne, Abingdon, United Kingdom). AM281 (CB1 receptor antagonist; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-carboxamide) and AM630 (CB2 receptor antagonist; 6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone) were obtained from Cayman Chemicals (Ann Arbor, MI). SB-366791 (N-(3-methoxyphenyl)-4-chlorocinnamide), rhodamine 6G, cremophor, dimethyl sulphoxide (DMSO), urethane, and MIA were obtained from Sigma-Aldrich (St. Louis, MO). Solutions of CBD, AM281, AM630, and SB-366791 were prepared in vehicle (1:1:18; DMSO:cremophor:saline) on the day of use. rhodamine 6G (0.05%) and MIA were dissolved in saline. Physiological buffer (135 mM NaCl, 20 mM NaHCO3, 5 mM KCl, 1 mM MgSO4*7H2O, pH = 7.4) was prepared in the laboratory.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!